Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Ophthotech Gains Rights to PDL's Volociximab in AMD

Jan. 9, 2008

By Jennifer Boggs

Catalyst Partners with Centocor for Engineered Protease Drugs

Jan. 8, 2008

By Jennifer Boggs

Catalyst Partners with Centocor for Engineered Protease Drugs

Jan. 8, 2008

By Jennifer Boggs

NewCo News: Carigent Enters Drug Delivery with Nanoparticle Technology

Jan. 7, 2008

By Jennifer Boggs

NewCo News: Carigent Enters Drug Delivery with Nanoparticle Technology

Jan. 7, 2008

By Jennifer Boggs

Crucell Signs Sanofi Pasteur in $113M Rabies Antibodies Deal

Jan. 4, 2008

By Jennifer Boggs

Crucell Signs Sanofi Pasteur in $113M Rabies Antibodies Deal

Jan. 4, 2008

By Jennifer Boggs

Casting Wide Net, Addrenex Targets Adrenergic Pathways

Dec. 31, 2007

By Jennifer Boggs

Alexza Licenses Inhaled Fentanyl Product To Endo; $10M Up Front

Dec. 31, 2007

By Jennifer Boggs

Casting Wide Net, Addrenex Targets Adrenergic Pathways

Dec. 31, 2007

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...